Research programme: RNAi therapeutics - Alnylam/Arrowhead

Drug Profile

Research programme: RNAi therapeutics - Alnylam/Arrowhead

Latest Information Update: 13 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alnylam Pharmaceuticals; Novartis
  • Developer Alnylam Pharmaceuticals; Arrowhead Pharmaceuticals
  • Class RNA vaccines; Small interfering RNA; Viral vaccines
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Respiratory syncytial virus infections; Unspecified

Most Recent Events

  • 06 Apr 2016 Arrowhead Research Corporation is now called Arrowhead Pharmaceuticals
  • 09 Mar 2015 Arrowhead acquires RNAi research and development portfolio from Novartis
  • 10 Nov 2012 Preclinical trials in Respiratory syncytial virus infections in USA and Europe (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top